1959
DOI: 10.1111/j.1749-6632.1959.tb49234.x
|View full text |Cite
|
Sign up to set email alerts
|

Amino Acid and Fatty Acid Hydrazides: Chemistry and Action on Monoamine Oxidase

Abstract: Iproniazid (Marsilid") interferes with different enzyme systems. Evidence exists that monoamine oxidase (MAO) inhibition is responsible for some of the actions of the drug in humans, such as the beneficial effectsin mental depression and angina pectoris. On the other hand, the many side effects may also be due to this inhibition, which takes place in a variety of organ systems. I t was believed that, by increasing the organ specificity of the molecule, side effects could be diminished or avoided. Iproniazid Th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0
1

Year Published

1962
1962
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 24 publications
(4 citation statements)
references
References 0 publications
0
3
0
1
Order By: Relevance
“…Thus, the l -glutamic analog of iproniazide presents a preferential monoamine oxidase inhibition in the brain, 74 whereas the palmitoyl isopropylhydrazide demonstrates a clear cardiac selectivity ( Table 36.2 ). Systemic site-directed delivery, that is, to a specifi c internal site or organ through a selective transport, is very diffi cult to achieve.…”
Section: Site-directed Drug Deliverymentioning
confidence: 99%
“…Thus, the l -glutamic analog of iproniazide presents a preferential monoamine oxidase inhibition in the brain, 74 whereas the palmitoyl isopropylhydrazide demonstrates a clear cardiac selectivity ( Table 36.2 ). Systemic site-directed delivery, that is, to a specifi c internal site or organ through a selective transport, is very diffi cult to achieve.…”
Section: Site-directed Drug Deliverymentioning
confidence: 99%
“…Nonetheless, there is no clinical proof that MAO inhibitors reduce levels of toxic and prooxidant MAO products until now ( Tipton, 2018 ). In the clinic, selective MAO-A inhibitors are used as amine-depleting drugs against depression ( Kline, 1958 ; Zeller et al, 1959 ). In contrast, selective MAO-B inhibitors work as dopamine-sparing compounds against PD (selective MAO-B inhibitors) ( Birkmayer et al, 1983 ).…”
Section: Introductionmentioning
confidence: 99%
“…Начиная с конца 50-х гг. специалисты стали обсуждать возможность создания «органоспецифичных» ИМАО [40]. Идея состояла в том, что они должны были влиять на органы, в отношении которых проявляется лечебное действие, например головной мозг или сердце (ИМАО использовались при стенокардии), и быть индифферентными к органам, при воздействии на которые развиваются побочные и токсические эффект, например кишечник и печень (гепатотоксичность).…”
Section: Chronology Of the Creation And Introduction Into Practice Of...unclassified